Merck and the Vioxx Rut
Merck’s stock price is starting to climb out of its hole this year, but the drug giant still faces a long uphill climb fraught with obstacles if it ever plans to get to its pre-Vioxx scandal levels.
Merck’s (up $0.19 to $36.62, Charts) stock price gained more than 14 percent year-to-date through June 30, far outpacing the gains of drug industry as a whole and the S&P 500, which each rose 1.8 percent. Compare this to the market leader Pfizer (up $0.11 to $23.58, Charts), which has seen its price climb less than 1 percent year-to-date.Merck’s gain isn’t too shabby, considering the company’s stock plunged nearly 27 percent on its Day of Infamy — Sept. 30, 2004. That’s the day America’s no. 2 drugmaker pulled Vioxx, an arthritis painkiller, off the market, following a study that linked the drug to increased risks of heart attack and stroke. This has since been a major concern for the company, which not only lost $2.5 billion in annual sales but now faces about 11,500 Vioxx-related lawsuits.
See the full, original post here: https://money.cnn.com/2006/07/03/news/companies/merck/index.htm
TriMark Legal Funding was founded in 2003 and is one of America's original legal funding providers. TriMark provides pre-settlement funding and post-settlement funding to injured plaintiffs who are involved in personal injury lawsuits, employment litigation, work injury accidents and workers compensation lawsuits, mass tort litigation, and multidistrict litigation. We also provide post-settlement attorney funding and portfolio funding for law firms.
|Mass Torts Litigation||MDL|
Click here to see the original article.